FWIW
*Acadia has indicated that the average net realised cost of Daybue therapy per payer is $375000 pa.and is based on dosing assumptions-average weight of expected patient population-dosage compliance rates etc.This roughly equates 80% gross to net revenue on full dose.
*Using the above numbers it can be determined that to generate $90M in quarterly revenue the equivalent of approximately 960 patients need to be on full therapy.Similarly $100M revenue requires about 1060 patients.
*The last number of patients quoted to be on Daybue therapy was 862 patients.
These numbers are rubbery but may be useful when looking at next weeks Acadia Earnings Report.
Kens
FWIW*Acadia has indicated that the average net realised cost of...
-
- There are more pages in this discussion • 137 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.92 |
Change
0.130(0.94%) |
Mkt cap ! $1.779B | |||
| Open | High | Low | Value | Volume |
| $13.66 | $14.03 | $13.46 | $11.10M | 803.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1608 | $13.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.99 | 250 | 1 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |